Skip to main content
    H

    Heron Therapeuti (HRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.28
    -0.03 (-8.44%)

    Market Cap: $59.08M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Heron Therapeuti (HRTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Heron Therapeuti reported revenue of $154.90M for the fiscal year ended Dec 31, 2025, up 7.4% from the year before. That year, net income was -$20.20M with a net margin of -13.0%, operating cash flow was -$27.59M and free cash flow was -$27.91M. The quarter ended Sep 30, 2026 had revenue of $35.25M and net income of -$5.01M.

    Revenue and Margins

    The operating margin was -1.6% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $1.28M, a compound annual rate of 70.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$154.90M+7.4%73.3%-1.6%-13.0%
    Dec 2024$144.28M+13.6%73.2%-8.0%-9.4%
    Dec 2023$127.04M+18.0%48.8%-87.1%-87.0%
    Dec 2022$107.67M+24.7%49.0%-162.2%-169.1%
    Dec 2021$86.35M-2.6%46.7%-252.3%-255.6%
    Dec 2020$88.64M-39.3%59.2%-257.4%-256.4%
    Dec 2019$145.97M+88.4%57.8%-144.3%-140.3%
    Dec 2018$77.47M+151.8%64.5%-237.4%-230.8%
    Dec 2017$30.77M+2305.6%85.1%-632.4%-641.9%
    Dec 2016$1.28MN/A97.3%-13363.2%-13537.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$154.90M$144.28M$127.04M$107.67M$86.35M$88.64M$145.97M$77.47M$30.77M$1.28M
    Cost of revenue$41.35M$38.65M$65.11M$54.87M$46.02M$36.19M$61.62M$27.51M$4.59M$35.00K
    Gross profit$113.56M$105.64M$61.94M$52.80M$40.33M$52.45M$84.35M$49.96M$26.18M$1.24M
    Research and development$12.43M$16.68M$39.13M$82.70M$130.82M$174.53M$167.38M$140.03M$138.58M$103.13M
    Operating income-$2.54M-$11.53M-$110.61M-$174.66M-$217.83M-$228.16M-$210.69M-$183.94M-$194.56M-$170.91M
    Net income-$20.20M-$13.58M-$110.56M-$182.02M-$220.68M-$227.28M-$204.75M-$178.84M-$197.48M-$173.14M
    EBITDA$1.19M-$9.79M-$108.56MN/A-$214.45M-$224.61M-$205.23M-$183.14M-$192.57M-$168.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$35.25M$37.67M$34.71M$40.59M$38.21M$37.20M$38.90M$40.78M$32.81M$36.02M$34.67M$34.23M
    Gross profit$26.29M$26.09M$24.07M$29.47M$26.30M$27.34M$30.45M$30.55M$23.35M$25.51M$26.23M$24.35M
    Operating income-$1.67M-$2.04M-$4.76M$38.00K-$4.09M-$1.64M$3.15M$4.17M-$4.46M-$6.45M-$4.80M-$10.22M
    Net income-$5.01M-$5.49M-$8.11M-$2.95M-$17.50M-$2.38M$2.63M$3.66M-$4.85M-$9.23M-$3.16M-$10.72M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, long-term debt of $140.64M exceeded cash and equivalents by $111.99M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$255.88M$233.15M$222.51M$250.95M$305.71M$353.56M$512.78M$462.18M$234.31M$67.48M
    Current assets$238.07M$209.01M$188.77M$205.44M$254.42M$314.20M$479.06M$447.25M$228.06M$62.14M
    Cash and equivalents$28.65M$25.80M$28.68M$15.36M$90.54M$105.14M$71.90M$31.84M$144.58M$13.41M
    Total liabilities$241.54M$266.80M$256.48M$237.38M$228.14M$117.06M$108.95M$92.02M$103.17M$88.73M
    Short-term debtN/A$3.04M$3.08M$2.69M$2.42M$10.05M$7.55M$4.57M$25.00M$0
    Long-term debt$140.64M$149.70M$173.75M$149.28M$149.08MN/AN/AN/A$0$50.00M
    Shareholder equity$14.33M-$33.65M-$33.97M$13.57M$77.57M$236.49M$403.83M$370.16M$131.14M-$21.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$230.45M$252.26M$246.22M$255.88M$248.95M$232.09M$235.75M$233.15M$220.78M$218.14M$217.89M$222.51M
    Total liabilities$225.53M$245.35M$237.08M$241.54M$234.06M$259.35M$264.20M$266.80M$260.78M$256.08M$251.65M$256.48M
    Cash and equivalents$11.60M$20.72M$26.12M$28.65M$43.07M$16.52M$19.27M$25.80M$25.74M$18.39M$20.45M$28.68M
    Shareholder equity$4.92M$6.91M$9.14M$14.33M$14.88M-$27.26M-$28.45M-$33.65M-$40.01M-$37.94M-$33.77M-$33.97M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$27.59M-$22.53M-$58.79M-$146.91M-$203.35M-$184.82M-$124.58M-$191.81M-$170.30M-$134.10M
    Capital expenditures$317.00K$1.71M$1.54M$1.82M$3.02M$6.81M$7.15M$9.17M$2.55M$3.13M
    Free cash flow-$27.91M-$24.23M-$60.33M-$148.74M-$206.38M-$191.63M-$131.73M-$200.98M-$172.85M-$137.23M
    Investing cash flow$16.01M$18.71M$18.00M-$3.32M$32.73M$208.96M-$21.78M-$278.55M$7.74M$14.88M
    Financing cash flow$14.43M$940.00K$54.11M$75.06M$156.03M$9.11M$186.43M$357.61M$293.73M$57.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$794.00K-$2.21M-$1.54M-$9.18M$1.33M-$10.87M-$8.87M-$11.78M$3.37M-$4.60M-$9.52M$2.46M
    Capital expenditures$102.00K$138.00K$391.00K$0$0$208.00K$109.00K$638.00K$431.00K$637.00K$0$250.00K
    Free cash flow-$896.00K-$2.35M-$1.93M-$9.18M$1.33M-$11.08M-$8.98M-$12.42M$2.94M-$5.24M-$9.52M$2.21M
    Last 12 quarters

    Frequently Asked Questions About HRTX

    What is Heron Therapeuti's annual revenue?

    Heron Therapeuti reported revenue of $154.90M for the fiscal year ended Dec 31, 2025.

    How fast is Heron Therapeuti's revenue growing?

    Revenue was up 7.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.

    Is Heron Therapeuti profitable?

    No. Heron Therapeuti reported net income of -$20.20M for the fiscal year ended Dec 31, 2025, with a net margin of -13.0%.

    How much free cash flow does HRTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$27.59M minus capital expenditures of $317.00K produced free cash flow of -$27.91M.

    How much debt does Heron Therapeuti have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $140.64M and cash and equivalents of $28.65M.